FIELD: medicine.
SUBSTANCE: invention relates to combating metabolic diseases. Method of treating one or more of overweight, obesity, visceral obesity, abdominal obesity, non-alcoholic steatohepatitis, polycystic ovary syndrome in a subject comprises administering to said subject therapeutic agent A and therapeutic agent B one or more times a day, wherein therapeutic agent A is a salicylate or a pharmaceutically acceptable salt thereof, and therapeutic agent B is trimetazidine or a pharmaceutically acceptable salt thereof.
EFFECT: invention provides higher efficiency of body weight reduction.
25 cl, 51 dwg, 51 ex
             
         
            
              
                | Title | Year | Author | Number | 
							
              
                | METHOD OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) WITH USING CYSTEAMINE PRODUCTS | 2008 | 
										Dokhil RandzhanShnajder Dzherri | RU2498795C2 | 
							
              
                | REGULATION OF METABOLISM USING MIR-378 | 2011 | 
										Olson Eric N.Carrer Michele | RU2585491C2 | 
							
              
                | NEW APPLICATIONS AND METHODS | 2017 | 
										Fansa-Berton, Paskal Elizabet ReneFalkao, Lejla DenizBili, Antuan SharlRoller, MarkBirtik, Simona | RU2765804C2 | 
							
              
                | D-TAGATOSE COMPOSITIONS AND METHODS OF PREVENTING AND TREATING ATHEROSCLEROSIS, METABOLIC SYNDROME AND SYMPTOMS THEREOF | 2009 | 
										Lodder Robert A.Kassis Liza A. | RU2484827C2 | 
							
              
                | APPLICATION OF NKG2D INHIBITORS FOR TREATING CARDIOVASCULAR AND METABOLIC DISEASES SUCH AS TYPE 2 DIABETES | 2010 | 
										Sjun NaSja Mintsan'Rolet Dehvid Kh.Petersen Jakob StenBedvarsdouttir Toura Brin'Ja | RU2566264C2 | 
							
              
                | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATED THERETO | 2018 | 
										Lan, Tszy-TszyanPauer, RonanYannikuris, AleksandrosJerramreddi, Tirupati Reddi | RU2765286C2 | 
							
              
                | GLUCURONIDATED ACETAMINOPHEN AS MARKER OF LIVER DISORDERS | 2009 |  | RU2555331C2 | 
							
              
                | NALMEFEN, NALTREXONE OR DERIVATIVES THEREOF FOR USE IN TREATING (NON)-ALCOHOLIC STEATOHEPATITIS OR NON-ALCOHOLIC FATTY LIVER DISEASE | 2017 | 
										Wu, Edwin, ScChiu, Peter, J.S.Hsu, May, Mei-Chi | RU2717677C1 | 
							
              
                | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION AND ISCHEMIC DAMAGE | 2012 | 
										Dokhil RandzhanFillips Syuzan A. | RU2638807C2 | 
							
              
                | CONCENTRATED THERAPEUTIC PHOSPHOLIPIDE COMPOSITIONS | 2010 |  | RU2642653C2 |